SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...

A further presentation during the same symposium at AD/PD 2025 focused on how MRI methods could be accelerated to improve ...

Encouraging interim results have supported Roche’s decision to move trontinemab into a pivotal Phase III programme.

Current biomarkers of cognitive impairment in individuals with Alzheimer’s disease perform poorly. Now, a stronger predictor ...

ProMIS expects to report six-month interim results from PRECISE-AD in the first half of 2026, with topline results ...

Here are some stocks to watch on Friday: ...

Alzinova AB (publ) (ticker: ALZ) today announces that the final analysis of data from the Phase 1b clinical study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's dis ...

announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab ... Based on its corporateconcept of "human health care (hhc)," Eisai has taken on ...

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of ...

The first similar pathology is the amyloid beta protein, which accumulates in large quantities identified in the brain of an ...

Research indicates amyloid beta plaques, sticky clumps of protein that accumulate in the brain, contribute to Alzheimer’s disease. The main theory on Alzheimer’s development is the amyloid cascade ...

Cerebral amyloid angiopathy (CAA) is driven by vascular Aβ (amyloid‐beta) deposition, which can be detected as reduced Aβ species in cerebrospinal fluid (CSF). We sought to identify relationships ...